Play Video
1
The Next Big Thing In Biotech: Biogen Idec
The Next Big Thing In Biotech: Biogen Idec
::2011/10/22::
Play Video
2
Biogen Idec Tapping into Denmark
Biogen Idec Tapping into Denmark's Strong Biotech Cluster
::2013/04/25::
Play Video
3
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
::2012/03/23::
Play Video
4
Manufacturing Drugs at Large Scale
Manufacturing Drugs at Large Scale
::2012/02/02::
Play Video
5
Biogen Idec: Caring Deeply - Changing Lives
Biogen Idec: Caring Deeply - Changing Lives
::2013/02/09::
Play Video
6
Time-lapse of Construction of Biogen Idec - Building 26 by OxBlue.com
Time-lapse of Construction of Biogen Idec - Building 26 by OxBlue.com
::2012/11/20::
Play Video
7
NBC News Report on Nrf2 vs MS - BioGen Idec
NBC News Report on Nrf2 vs MS - BioGen Idec's BG12 Drug vs Protandim
::2013/11/20::
Play Video
8
Partnerships TV: Jorge Guerra, Biogen Idec
Partnerships TV: Jorge Guerra, Biogen Idec
::2012/07/12::
Play Video
9
Boston Properties & Biogen Idec - Weston Corporate Center Sustainable Innovation
Boston Properties & Biogen Idec - Weston Corporate Center Sustainable Innovation
::2010/03/01::
Play Video
10
La Fundación Biogen Idec reconoce la investigación básica de jóvenes españoles
La Fundación Biogen Idec reconoce la investigación básica de jóvenes españoles
::2012/03/20::
Play Video
11
News Update: Biogen Idec Inc. CEO & COO to Retire, Company Announces Changes in Management (BIIB)
News Update: Biogen Idec Inc. CEO & COO to Retire, Company Announces Changes in Management (BIIB)
::2010/06/08::
Play Video
12
Biogen Idec
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US
::2013/03/28::
Play Video
13
Gilmore O
Gilmore O'Neill, VP, Biogen Idec Medical Research
::2010/11/18::
Play Video
14
Biogen Idec Inc Corporate Office Contact Information
Biogen Idec Inc Corporate Office Contact Information
::2013/03/27::
Play Video
15
Jamie Manning, Manager for the Digital Communications Team at Biogen Idec - DigiPharm 2012
Jamie Manning, Manager for the Digital Communications Team at Biogen Idec - DigiPharm 2012
::2013/05/13::
Play Video
16
Joydeep Ganguly,  Director, Biogen Idec GMP Sourcing and Procurement
Joydeep Ganguly, Director, Biogen Idec GMP Sourcing and Procurement
::2010/06/15::
Play Video
17
BiogenIdec Blues Band
BiogenIdec Blues Band
::2013/06/20::
Play Video
18
Is Biogen Idec Bottoming?
Is Biogen Idec Bottoming?
::2011/11/16::
Play Video
19
Tracy Callahan and Shanon Harrington Discuss the Biogen Idec Community Labs Scholarship
Tracy Callahan and Shanon Harrington Discuss the Biogen Idec Community Labs Scholarship
::2012/06/18::
Play Video
20
Kenan Fellows Program & Biogen Idec - The Impact of Corporate Sponsorship in the Classroom
Kenan Fellows Program & Biogen Idec - The Impact of Corporate Sponsorship in the Classroom
::2012/09/19::
Play Video
21
Biogen Idec receives statewide award for math and science
Biogen Idec receives statewide award for math and science
::2011/04/22::
Play Video
22
Stocks to Watch: Biogen Idec, Teppco, Enterprise Products - Bloomberg
Stocks to Watch: Biogen Idec, Teppco, Enterprise Products - Bloomberg
::2009/06/29::
Play Video
23
Biogen Idec Receives Corporate Friendship Award From Boston Cares - November 2013
Biogen Idec Receives Corporate Friendship Award From Boston Cares - November 2013
::2013/11/22::
Play Video
24
Steven Holtzman, Biogen Idec on why Pharma investors should focus more on product than return
Steven Holtzman, Biogen Idec on why Pharma investors should focus more on product than return
::2012/09/26::
Play Video
25
(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc.
::2014/03/20::
Play Video
26
Biogen Idec forges a $320M gene editing deal aimed at curing inherited blood disorders
Biogen Idec forges a $320M gene editing deal aimed at curing inherited blood disorders
::2014/01/10::
Play Video
27
Biogen Idec
Biogen Idec
::2014/03/08::
Play Video
28
Biogen Idec Prezi
Biogen Idec Prezi
::2014/03/07::
Play Video
29
Novartis
Novartis' Multiple Sclerosis Pill (Gilenya) Joepardizing the Biogen Idec Franchise?
::2010/10/05::
Play Video
30
(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc.
::2014/01/29::
Play Video
31
Pete presents to the staff at Biogen Idec
Pete presents to the staff at Biogen Idec
::2013/06/14::
Play Video
32
The Tony Kingsley, EVP, Global Commercial Operations, Biogen Idec Executive Profile
The Tony Kingsley, EVP, Global Commercial Operations, Biogen Idec Executive Profile
::2013/08/02::
Play Video
33
Biogen Idec
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
::2013/03/28::
Play Video
34
Biogenidec Weston Snap Turtle
Biogenidec Weston Snap Turtle
::2012/08/13::
Play Video
35
Chemical Inventory Management | Biogen Idec
Chemical Inventory Management | Biogen Idec
::2013/04/05::
Play Video
36
Entrevista a Sacramento Rodríguez, premi nacional de la Fundació Biogen Idec Joves Investigadors
Entrevista a Sacramento Rodríguez, premi nacional de la Fundació Biogen Idec Joves Investigadors
::2013/04/17::
Play Video
37
Biogen idec driving to hospital UMM
Biogen idec driving to hospital UMM
::2014/03/25::
Play Video
38
Elan Corp, Biogen Idec Asked Regulators To Change Its Label For MS Drug Tysabri
Elan Corp, Biogen Idec Asked Regulators To Change Its Label For MS Drug Tysabri
::2010/12/22::
Play Video
39
Biogen Idec Testimonial for vCom Solutions
Biogen Idec Testimonial for vCom Solutions
::2012/12/05::
Play Video
40
Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence
Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence
::2010/04/27::
Play Video
41
Biogen Idec
Biogen Idec
::2012/10/14::
Play Video
42
50th anniversary wish from World Hemophilia Day sponsor Biogen Idec Hemophilia
50th anniversary wish from World Hemophilia Day sponsor Biogen Idec Hemophilia
::2013/04/08::
Play Video
43
Biogen Idec
Biogen Idec's TECFIDERA Approved in US as a First-Line Oral Treatment for Multiple Sclerosis
::2013/03/28::
Play Video
44
Rick Day,  Program Manager, Biogen Idec Patient Services
Rick Day, Program Manager, Biogen Idec Patient Services
::2010/06/15::
Play Video
45
BIO-Europe Spring 2014: Interview with John McDonald, Biogen Idec
BIO-Europe Spring 2014: Interview with John McDonald, Biogen Idec
::2014/04/08::
Play Video
46
Biogen Idec Said A Late-Stage Trial Showed Its MS Drug Was Better Than A Placebo
Biogen Idec Said A Late-Stage Trial Showed Its MS Drug Was Better Than A Placebo
::2011/04/11::
Play Video
47
Video Noticia
Video Noticia 'V Premios Biogen Idec Jovenes Investigadores'
::2011/03/16::
Play Video
48
Sha Mi (Misha), PhD.,  Principal Investigator, Biogen Idec Neurobiology
Sha Mi (Misha), PhD., Principal Investigator, Biogen Idec Neurobiology
::2010/06/15::
Play Video
49
Biogen Idec Exhibit
Biogen Idec Exhibit
::2013/11/10::
Play Video
50
Biogen Idec Reported In Line Q2 EPS, Topped Revenue Estimates
Biogen Idec Reported In Line Q2 EPS, Topped Revenue Estimates
::2011/07/26::
NEXT >>
RESULTS [51 .. 101]
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Biogen Idec, Inc.
Type Public
Traded as NASDAQBIIB
NASDAQ-100 Component
S&P 500 Component
Industry Biotechnology
Founded 2003
Headquarters Weston, Massachusetts, U.S.
Key people William D. Young (Chairman) George A. Scangos (CEO)
Products Rituxan
Avonex
Tysabri
Revenue Increase US$ 5.048 billion (2011)[1]
Operating income Increase US$ 1.724 billion (2011)[1]
Net income Increase US$ 1.266 billion (2011)[1]
Total assets Increase US$ 9.049 billion (2011)[1]
Total equity Increase US$ 6.426 billion (2011)[1]
Employees 4,850 (2010)[1]
Website www.biogenidec.com

Biogen Idec, Inc. is an American biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer.[2] The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and Howard Birndorf).[3] Biogen, one of the oldest biotechnology companies, was founded in 1978 in Geneva[4] by several biologists, including Kenneth Murray of the University of Edinburgh, Phillip Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase) and Charles Weissmann, University of Zurich (who contributed the first product interferon-alpha).

Biogen Idec stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100.

Products[edit]

Biogen Idec's products include multiple sclerosis (MS) treatments Avonex (interferon beta-1a) and Tysabri (natalizumab); the latter is also approved for treatment of Crohn's disease, and is co-marketed with Élan. Biogen Idec also makes Rituxan (rituximab), a treatment for non-Hodgkin's lymphoma which is also approved for rheumatoid arthritis; Rituxan is co-marketed with Genentech.[5] The company acquired Fumaderm (fumaric acid esters), a psoriasis treatment (licensed in Germany) when it acquired Fumapharm AG in 2006. In December, 2007, Biogen Idec sold the U.S. rights for Zevalin (ibritumomab tiuxetan), another treatment for non-Hodgkin's lymphoma, to Cell Therapeutics, but continues to produce it for European marketing partner Bayer Schering Pharma. In 2006, the company sold rights for Amevive (alefacept), another psoriasis treatment, to Astellas Pharma, continuing to manufacture the drug under contract.[6]

The company's drug BG-12 (dimethyl fumarate) was tested for effectiveness in relapsing-remitting multiple sclerosis. When given twice daily, BG-12 cut the relapse rate by 44 percent at two years compared with a placebo. When given three times a day, it cut the relapse rate by 51 percent.[7] In a press release dated March 27, 2013 the FDA announced that it had approved BG-12 to be marketed under the brand name Tecfidera.[8] According to the FDA Approved Labeling Text “The efficacy and safety of TECFIDERA were demonstrated in two studies... that evaluated TECFIDERA taken either twice or three times a day in patients with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA had a statistically significant effect on the relapse and MRI endpoints” monitored in both tests. [9]


Locations of operation[edit]

Biogen Idec is headquartered in Weston, Massachusetts, and operates research and development facilities in Cambridge, MA. Biogen Idec operates manufacturing facilities in Kendall Square and in Research Triangle Park, North Carolina. The company has also built a Large Scale Manufacturing plant in Hillerød, Denmark.

Biogen Idec maintains its international headquarters in Zug, Switzerland, and operates an International regulatory & clinical center of excellence in Maidenhead, UK. Biogen Idec has direct commercial affiliates in Germany, France, Spain/Portugal, UK/Ireland, the Benelux, Sweden, Denmark, Norway, Finland, Austria, Canada, Japan, China, India and Australia. In Italy and in Switzerland, Biogen Idec markets its products through two joint venture companies set up with the privately held Italian company Dompe Biotec.

Competitors[edit]

Biogen Idec's principal competitors include Teva, Sanofi Aventis, Serono, Novartis, and Bayer Schering Pharma.

As of 2004, Biogen Idec derives most of its income from sales of multiple sclerosis treatment Avonex and from partnership royalties on Rituxan from Genentech, which markets Rituxan in the US. Roche markets Rituxan outside the US as MabThera.

Management[edit]

Biogen Idec is managed day-to-day by an executive group composed of nine officers. As customary for a publicly traded company, BIIB is also overseen by a board of directors that votes on important company decisions. The executive chairman and chief executive officer both hold positions on the board of directors. The directors are Bruce R. Ross (chairman), George A. Scangos Ph.D.(CEO), Lawrence C. Best, Marijn E. Dekkers, Alan B. Glassberg, Thomas F. Keller, Nancy L. Leaming, Robert W. Pangia, Cecil Pickett, Lynn Schenk, Phillip A. Sharp, and William D. Young.[10]

Investor Carl Icahn launched a proxy fight seeking to elect three of his own nominees to the Biogen Idec board at the company's June 19, 2008, annual meeting of shareholders. Icahn's nominees were Alexander J. Denner, Anne B. Young, and Richard C. Mulligan, all of whom had served on the board of ImClone Systems since Icahn took control of that company.[11] None of Icahn's nominees were elected.

Citing a market capitalization of US$67 billion and stock appreciation of 92%, Biogen Idec was reported as the number 3 ranked drug company of 2013 by Forbes Magazine. [12]

Natalizumab withdrawal[edit]

On February 28, 2005, Biogen Idec and marketing partner Elan Pharmaceuticals voluntarily suspended marketing of natalizumab, and also suspended dosing in all ongoing clinical trials. Natalizumab had been approved in the US in November 2004 for treatment of patients with relapsing remitting MS.

The two companies announced the suspension after two participants involved in one study were diagnosed with a severe brain condition, progressive multifocal leukoencephalopathy (PML), after two years of combination therapy with Biogen's version of interferon beta-1a. One of those two patients died. Subsequently, another patient who had previously died in a separate clinical trial of natalizumab in patients with Crohns disease was re-evaluated as having had PML. In total, 3 cases of PML were identified, of which 2 cases were fatal.[13][14]

On 08/2008 the company announced 2 more cases of PML in Europe.[15]

Biogen Idec stock lost more than 40% of its value when the drug suspension news was released on February 28, 2005.

Biogen Idec Foundation[edit]

Instituted in 2008, the Biogen Idec Foundation's mission is to improve the quality of peoples' lives and contribute to the vitality of the communities in which Biogen Idec operates, with a special emphasis on innovative ways to promote science literacy and encourage young people to consider science careers.

Restatement[edit]

On July 19, 2001, the company adopted the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 101 in the fourth quarter of fiscal 2000 effective as of January 1, 2000, which resulted in the restatement of the financial results for the three and six months ended June 30, 2000.[16]

See also[edit]

References[edit]

  1. ^ a b c d e f "2010 Form 10-K, Biogen Idec, Inc.". United States Securities and Exchange Commission. 
  2. ^ "Biogen Idec Inc (BIIB.O) Company Profile | Reuters.com". reuters.com. Retrieved 13 August 2012. 
  3. ^ "Why San Diego Has Biotech", Fikes, Bradley J. San Diego Metropolitan, April 1999. Accessed June 20, 2008.
  4. ^ "Biogen History",
  5. ^ Biogen Idec (2008). "Product Pipeline" in 2007 Annual Report
  6. ^ Biogen Idec (2008-02-14). "SEC Form 10-K". pp. 1, 11. Retrieved 2008-06-07. 
  7. ^ Clarke, Toni (2011-10-26). "UPDATE 6-Biogen's BG-12 seen topping MS drug league". Reuters.com. Retrieved 26 December 2011. 
  8. ^ "FDA approves new multiple sclerosis treatment: Tecfidera". US Food and Drug Administration News and Events. FDA. Retrieved 10 November 2013. 
  9. ^ "NDA 204063 FDA Approved Labeling Text". NDA 204063 FDA Approved Labeling Text. US Food and Drug Administration. Retrieved 10 November 2013. 
  10. ^ Biogen Idec. "Board of Directors". Retrieved 2008-06-06. [dead link]
  11. ^ Icahn, Carl C. et al. (2008-05-16). "Definitive proxy statement on SEC Form DEFC14A". Retrieved 2008-06-07.  SEC accession number 0000928475-08-000185.
  12. ^ "Grading Pharma in 2013". Forbes. December 31, 2013. 
  13. ^ Kleinschmidt-DeMasters BK, Tyler KL (2005). "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis". N. Engl. J. Med. 353 (4): 369–74. doi:10.1056/NEJMoa051782. PMID 15947079. 
  14. ^ Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005). "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". N. Engl. J. Med. 353 (4): 375–81. doi:10.1056/NEJMoa051847. PMID 15947078. 
  15. ^ Goldstein, Jacob (2008-08-01). "Brain Infections Return for Multiple Sclerosis Drug Tysabri". The Wall Street Journal. Retrieved 2008-08-01. 
  16. ^ "IDEC Pharmaceuticals Reports Second Quarter 2001 Results; Rituxan Sales Increase 86% Over 2Q 2000 and Earnings Increase to $0.15 Per Share;BIOWIRE2K". 

External links[edit]

Coordinates: 42°21′58.3″N 71°5′13.2″W / 42.366194°N 71.087000°W / 42.366194; -71.087000

Wikipedia content is licensed under the GFDL License

Mashpedia enables any individual or company to promote their own Youtube-hosted videos or Youtube Channels, offering a simple and effective plan to get them in front of our engaged audience.

Want to learn more? Please contact us at: hello@mashpedia.com

Powered by YouTube
LEGAL
  • Mashpedia © 2014